Can histopathology guide immunosuppression for cardiac allograft rejection in the light of new techniques?
Billingham
M E
ME
Cardiothoracic Surgery Department, Stanford University, California, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D015415:Biomarkers; D015815:Cell Adhesion Molecules / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D006084:Graft Rejection / Q000473:pathology* / Q000517:prevention & control; D053804:Granzymes; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology*; D006801:Humans; D007165:Immunosuppression Therapy; D008285:Major Histocompatibility Complex; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D012697:Serine Endopeptidases / Q000032:analysis / Q000096:biosynthesis; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D016207:Cytokines; D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D054353:Perforin; D053804:Granzymes; D012697:Serine Endopeptidases; C509212:GZMA protein, human